Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does FIBRINOGEN HUMAN Cause Thrombophlebitis superficial? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Thrombophlebitis superficial have been filed in association with FIBRINOGEN HUMAN (TachoSil). This represents 1.2% of all adverse event reports for FIBRINOGEN HUMAN.

5
Reports of Thrombophlebitis superficial with FIBRINOGEN HUMAN
1.2%
of all FIBRINOGEN HUMAN reports
0
Deaths
0
Hospitalizations

How Dangerous Is Thrombophlebitis superficial From FIBRINOGEN HUMAN?

Of the 5 reports.

Is Thrombophlebitis superficial Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for FIBRINOGEN HUMAN. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does FIBRINOGEN HUMAN Cause?

Foetal exposure during pregnancy (40) No adverse event (38) Off label use (38) Drug ineffective (34) Hypotension (31) Foetal anaemia (27) Foetal growth restriction (27) Haemorrhage in pregnancy (26) Anaphylactic shock (25) Maternal exposure during pregnancy (25)

What Other Drugs Cause Thrombophlebitis superficial?

DROSPIRENONE\ETHINYL ESTRADIOL (160) LENALIDOMIDE (121) ETHINYL ESTRADIOL\ETONOGESTREL (93) RIVAROXABAN (82) YAZ (78) YASMIN (65) TESTOSTERONE (62) HUMAN IMMUNOGLOBULIN G (43) ADALIMUMAB (40) CAPECITABINE (29)

Which FIBRINOGEN HUMAN Alternatives Have Lower Thrombophlebitis superficial Risk?

FIBRINOGEN HUMAN vs FIBRINOGEN HUMAN\HUMAN THROMBIN FIBRINOGEN HUMAN vs FIBRINOGEN HUMAN\THROMBIN HUMAN FIBRINOGEN HUMAN vs FIDAXOMICIN FIBRINOGEN HUMAN vs FILGOTINIB FIBRINOGEN HUMAN vs FILGRASTIM

Related Pages

FIBRINOGEN HUMAN Full Profile All Thrombophlebitis superficial Reports All Drugs Causing Thrombophlebitis superficial FIBRINOGEN HUMAN Demographics